Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR/Cas9 gene therapy for sickle cell disease
Ajeet Singh(Dow University of Health Sciences), Aymar Akilimali(Roslin Institute), Zainab Nazir(Dow University of Health Sciences), Hamza Irfan(Shaikh Zayed Postgraduate Medical Institute), Eeshal Fatima(Services Institute of Medical Sciences), Amogh Verma
Cited by 87
Related Papers
Impacts of the advancement in artificial intelligence on laboratory medicine in low‐ and middle‐income countries: Challenges and recommendations—A literature review
|Health Science Reports|2024|62
Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa
|Annals of Medicine and Surgery|2023|30
Self-medication and Anti-malarial Drug Resistance in the Democratic Republic of the Congo (DRC): A silent threat
|Tropical Medicine and Health|2022|29
Barriers Encountered Toward Pursuing a Neurosurgical Career: A Cross-Sectional Study Among Medical Students, Interns, and Junior Doctors in Africa
|World Neurosurgery|2022|26
The unmet need of organ transplantation in Africa
|International Journal of Surgery|2023|21